Bilateral Hemopneumothorax in COVID-19

Omer Salah 1, Mohannad Faisal 1, Israa Alshahwani 2, Abdelhaleem Elhiday 1

1. Internal Medicine, Hamad Medical Corporation, Doha, Qatar 2. Epidemiology and Public Health, Hamad Medical Corporation, Doha, Qatar

Corresponding author: Omer Salah, omersalah3475@gmail.com

Abstract

A 50-year-old previously healthy male presented with fever and cough for seven days, positive for COVID-19, and was admitted to Hazm Meberik General Hospital and treated as a case of severe COVID-19 pneumonia. After improvement, he was transferred to a quarantine facility, and he later developed bilateral hemopneumothorax requiring bilateral chest tubes. High-resolution CT showed bilateral emphysematous bullous disease. Tuberculosis workup was negative, and alpha 1 anti-trypsin levels were normal. Repeated Chest X-ray showed improvement and chest tubes were removed. The patient was discharged with follow-up with the thoracic surgery clinic.

Categories: Internal Medicine
Keywords: pneumothorax, covid 19

Introduction

COVID-19, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in late 2019 as a cause of pneumonia.

Secondary spontaneous pneumothorax (SSP) is defined as pneumothorax that presents as a complication of underlying lung disease [1]. Nearly every lung disease can be complicated by SSP, although the most commonly associated diseases are chronic obstructive pulmonary disease and, in endemic areas, tuberculosis (TB). Other common causes include cystic fibrosis (CF), primary or metastatic lung malignancy, and necrotizing pneumonia [2].

Here, we present a case report of a patient who acquired COVID-19 pneumonia. Initially, he was having mild symptoms, but later he suddenly developed bilateral pneumohemothorax and bullous emphysematous disease, as revealed on high-resolution CT. These finding are not commonly known complications of COVID-19 and are mostly only presented in case reports.

We also reviewed some articles on the development of pneumothorax as a complication of COVID-19-associated pneumonia including tension pneumothorax, pneumomediastinum, and subcutaneous emphysema, in addition to case reports on cystic changes within the lungs as a sequel of COVID-19 infection.

Case Presentation

A 50-year-old previously healthy male presented to Al Wakrah Hospital with a seven-day history of fever and dry cough but did not experience any shortness of breath, chest pain, or palpitations. There was no history of smoking or alcohol use. He lives with three others in an apartment and works as a driver. Review of the system was unremarkable. Temperature was 37.1°C, pulse rate was 98 beats per minute, respiratory rate was 18 breaths/minute, and blood pressure (BP) was 145/85 mmHg. Chest examination showed equal breath sounds and no added sounds, and remaining of the examination was unremarkable. Initial chest X-ray (CXR) only showed prominent bronchovascular marking (Figure 1).
FIGURE 1: Chest X-ray on admission showing prominent bronchovascular markings and no infiltration

COVID-19 PCR (polymerase chain reaction) was positive. The patient was discharged with home isolation and was educated to come back if he developed worsening symptoms.

After six days, the patient developed high-grade fever, body aches, and shortness of breath that was increasing for the past three days. He was brought to the hospital through ambulance.

He was found to be febrile. Temperature was 39.1°C, respiratory rate was 22 breaths/minute, BP was 115/65 mmHg, pulse was 108 beats/minute, and SpO\textsubscript{2} was 85% on room air. He was kept on 6L face mask and maintained a saturation of 95%. Examination showed equal breath sounds with bilateral crepitations.

On re-evaluation, he became more breathless and tachypneic (RR = 38) and saturation was 95% on a 15L non-rebreather mask. CXR showed multiple bilateral airspace infiltrates representing COVID-19 pneumonia (Figure 2). He was transferred to the intensive care unit (ICU) for continuity of care and was treated as a case of severe COVID pneumonia; Lab investigations are shown in Table 1.
FIGURE 2: Bilateral infiltrates
<table>
<thead>
<tr>
<th>Group</th>
<th>Detail</th>
<th>Value, w/Units</th>
<th>Flags</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>POC BGs</td>
<td>pH Art-POC</td>
<td>7.491</td>
<td>Hi</td>
<td>7.350-7.450</td>
</tr>
<tr>
<td></td>
<td>PO$_2$ Art-POC</td>
<td>93 mmHg</td>
<td></td>
<td>83-108</td>
</tr>
<tr>
<td></td>
<td>PCO$_2$ Art-POC</td>
<td>36 mmHg</td>
<td></td>
<td>35-45</td>
</tr>
<tr>
<td></td>
<td>Na Art-POC</td>
<td>130 mmol/L</td>
<td>Low</td>
<td>135-145</td>
</tr>
<tr>
<td></td>
<td>K Art-POC</td>
<td>3.3 mmol/L</td>
<td>Low</td>
<td>3.5-5.0</td>
</tr>
<tr>
<td></td>
<td>BG Hct Art-POC</td>
<td>42.0%</td>
<td></td>
<td>36.0-50.0</td>
</tr>
<tr>
<td>General hematology</td>
<td>WBC</td>
<td>10.2 x 10$^3$/uL</td>
<td>Hi</td>
<td>4.0-10.0</td>
</tr>
<tr>
<td></td>
<td>RBC</td>
<td>5.3 x 10$^6$/uL</td>
<td></td>
<td>4.5-5.5</td>
</tr>
<tr>
<td></td>
<td>Hgb</td>
<td>15.9 gm/dL</td>
<td></td>
<td>13.0-17.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.9 x 10$^9$/uL</td>
<td>Hi</td>
<td>2.0-7.0</td>
</tr>
<tr>
<td></td>
<td>Lymphocyte</td>
<td>0.8 x 10$^9$/uL</td>
<td>Low</td>
<td>1.0-3.0</td>
</tr>
<tr>
<td>Coagulation</td>
<td>Prothrombin time</td>
<td>13.8 seconds</td>
<td>Hi</td>
<td>9.4-12.5</td>
</tr>
<tr>
<td></td>
<td>INR</td>
<td>1.2</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D-dimer</td>
<td>1.47 mg/L FEU</td>
<td>Hi</td>
<td>0.00-0.49</td>
</tr>
<tr>
<td></td>
<td>APTT</td>
<td>36.0 seconds</td>
<td></td>
<td>25.1-36.5</td>
</tr>
<tr>
<td>Blood chemistry</td>
<td>Urea</td>
<td>4.1 mmol/L</td>
<td></td>
<td>2.8-8.1</td>
</tr>
<tr>
<td></td>
<td>Creatinine</td>
<td>99 umol/L</td>
<td></td>
<td>62-106</td>
</tr>
<tr>
<td></td>
<td>Total protein</td>
<td>75 gm/L</td>
<td></td>
<td>66-87</td>
</tr>
<tr>
<td></td>
<td>Albumin level</td>
<td>27 gm/L</td>
<td>Low</td>
<td>35-52</td>
</tr>
<tr>
<td></td>
<td>Alkaline phosphatase</td>
<td>197 U/L</td>
<td>Hi</td>
<td>40-129</td>
</tr>
<tr>
<td></td>
<td>ALT</td>
<td>132 U/L</td>
<td>Hi</td>
<td>0-41</td>
</tr>
<tr>
<td></td>
<td>AST</td>
<td>81 U/L</td>
<td>Hi</td>
<td>0-40</td>
</tr>
<tr>
<td></td>
<td>G6PD screen</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CRP</td>
<td>133.1 mg/L</td>
<td>Hi</td>
<td>0.0-5.0</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Ferritin</td>
<td>8,382.0 ug/L</td>
<td>Hi</td>
<td>30.0-553.0</td>
</tr>
</tbody>
</table>

**TABLE 1: Basic labs investigation**

ALT, alanine amino transferase; ANC, absolute neutrophil count; APTT, activated partial thromboplastin time; Art, arterial; AST, aspartate amino transferase; BG, blood gas; CRP, C-reactive protein; G6PD, glucose 6 phosphate deficiency; Hct, hematocrit; Hgb, hemoglobin; INR, international normalized ratio; K, potassium; Na, sodium; POC, point of care; PO$_2$, partial pressure of oxygen; PCO$_2$, partial pressure of carbon dioxide; RBC, red blood cell count; WBC, white blood cell count

The patient did not require intubation. He was started on hydroxychloroquine for 10 days, cefuroxime and azithromycin for 7 days, tocilizumab IV 400 mg single dose, and methylprednisolone 40 IV every 12 hours for 5 days. He also received convalescent plasma. The patient started to improve in terms of oxygen requirements and symptoms. After seven days of ICU admission, his care was de-escalated to the ward, and on 2L nasal cannula he was saturating well. Four days later, he was transferred to a quarantine facility.

He was doing well until three days later where he started to deteriorate and developed shortness of breath and desaturation. Repeat CXR showed right-sided pneumothorax with mild shift of the mediastinum to the left side (Figure 3).
FIGURE 3: Right-sided pneumothorax with midline shift toward the left side

Chest tube was inserted on the right side, and the right lung started to expand (Figure 4).

FIGURE 4: Right-sided chest tube insertion shows expansion of the right lung
The patient was transferred back to the hospital ICU. He was improving. Daily CXR was performed for
follow-up, and three days later, repeat CXR showed newly developed left-sided pneumothorax (Figure 5).

Chest tube was inserted on the left side.

High-resolution CT (Figure 6) was performed, which showed bilateral emphysematous bullous complicated
by pneumothorax due to rupture bullae with giant subpleural bullae in the left side measuring 19 x 7 cm and
also a large one in the right side showing air-fluid level measuring 5.5 x 4.5 cm, indicating infected bullae
versus lobulated hydropneumothorax. Also, there are bronchiectasis changes with multiple patchy areas of
ground glass attenuation mainly in the mid and lower lobe, and diffuse centrilobular, peribronchial septal
thickening and patchy nodular opacities were noted.
The right chest tube was removed as it stopped bubbling. He was saturating well on 2L nasal cannula. The patient was kept on salbutamol and tiotropium.

Two sets of acid-fast bacilli (AFB) sputum for TB, TB PCR, and culture were negative. Alpha 1 anti-trypsin level was normal.

Follow-up CXR for the next five days showed no changes. On the sixth day, repeated CXR showed bilateral hydropneumothorax mostly on the left lung (Figure 7).
FIGURE 7: Bilateral air-fluid level mostly on the left lung

The patient was well, had no new symptoms, and was saturating well on 1L nasal cannula.

Another chest tube was inserted on the left side that drained 500 mL of blood along with air.

Repeat CXR after insertion of the chest tube on the next day showed resolution of hemothorax on the left side, and the right hemothorax resolved spontaneously (Figure 8).

FIGURE 8: Resolution of bilateral hydropneumothorax

The small chest tube from the left side was removed, and the large bore tube was left. COVID 19 PCR was repeated and was negative. The chest tube stopped to bubble, not draining any fluid. The chest tube was clamped and CXR was repeated (Figure 9).
FIGURE 9: Repeat chest X-ray showing clamped chest tubes and inflated lungs

The chest tube was removed and the patient was monitored for four hours. He was feeling well and was discharged with follow-up with the thoracic surgeon.

Discussion
In the described case, the patient with COVID-19 pneumonia had initially mild symptoms that later progressed requiring ICU admission but not requiring endotracheal intubation. As he improved, his hospital course got complicated with the development of bilateral pneumohemothorax with underlying bullae formation noticed in CT scan of the chest. He managed by placing bilateral chest tubes and was discharged in good health.

During his stay, he was worked up for other causes of the pneumothorax; two sets of TB AFB smear sputum, culture, and PCR were sent, which turned out negative. Alpha 1 anti-trypsin level was normal. His CT of the chest showed bilateral emphysematous bullous complicated by pneumothorax due to rupture bullae with giant subpleural bullae along with lobulated hydro pneumothorax.

In view of the lack of previous history of underlying lung disease and the normal CXR on presentation along with the exclusion of some of the common causes of secondary pneumothorax, we think that COVID-19 pneumonia and its complication induced cystic changes within the lung and lead to spontaneous pneumothorax.

Pneumothorax has been reported as a complication of COVID-19 pneumonia and sometimes as a presenting feature reported by other case reports [3-9].

In our case, in addition to cases reported by Liu et al. [10], cystic changes within the lungs happened as a sequel of COVID-19 pneumonia, as evidenced by CT scan, and this case did not require intubation during the course of the illness [10]. We think that the COVID-19 infection and its sequel may have had a destructive effect on the lung parenchyma causing cystic changes and may have lead to subsequent pneumothorax, which need further reports and studies to be proven.

Conclusions
COVID-19 could be a probable cause of spontaneous pneumothorax secondary to cystic changes and bullae formation within the lung parenchyma and should be kept in mind when evaluating patients with COVID-19 and shortness of breath, but we need further studies on the association between and pathophysiology of the occurrence of infection and pneumothorax.

Additional Information
Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References